Buy Vilitra

Vilitra

Vilitra: Vardenafil Pill Overview

Vilitra contains vardenafil as its active component and is prescribed for the treatment of erectile dysfunction (ED). It belongs to the phosphodiesterase-5 (PDE5) inhibitor class and is available in pill form in strengths of 10 mg, 20 mg, 40 mg, and 60 mg. In the United Kingdom, Vilitra is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).

How Vilitra Works in the Body

Vardenafil belongs to the PDE5 inhibitor class. By blocking the enzyme phosphodiesterase-5, it prevents the breakdown of cyclic guanosine monophosphate (cGMP) within the smooth muscle cells of the penis. Elevated cGMP leads to relaxation of these muscles, allowing increased blood flow into the corpora cavernosa during sexual stimulation. This physiological response facilitates the development and maintenance of an erection. The onset of action typically occurs within 30-60 minutes, with a duration of effect up to 4-5 hours. Vardenafil is absorbed rapidly after oral administration, reaching peak plasma concentrations within about an hour. It is metabolised primarily by the liver enzyme CYP3A4 and excreted in the urine and feces.

Conditions Treated by Vilitra

Vilitra is approved by the MHRA for the treatment of erectile dysfunction in adult men. The medication is intended for use on an as-needed basis before sexual activity. It is not indicated for other conditions such as pulmonary arterial hypertension or benign prostatic hyperplasia.

Patient Suitability and Contraindications

Who Should Use Vilitra?

• Adult men with a clinical diagnosis of erectile dysfunction.
• Individuals who are able to engage in sexual activity within 30-60 minutes after dosing.
• Patients whose cardiovascular status has been evaluated and deemed stable for sexual activity.

Absolute Contraindications

• Concomitant use of any nitrate medication (e.g., nitroglycerin, isosorbide dinitrate) - the combination can cause severe hypotension.
• Known hypersensitivity to vardenafil or any excipients in the tablet.
• Use in patients with hereditary retinal disorders such as retinitis pigmentosa.

Relative Contraindications

• Unstable angina, recent myocardial infarction, or uncontrolled hypertension.
• Severe hepatic impairment (Child-Pugh C) or severe renal impairment (eGFR < 30 mL/min/1.73 m²) - dose adjustment may be required.
• Concurrent use of potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) - may increase vardenafil exposure.
• Patients taking alpha-blockers for benign prostatic hyperplasia; a 30-minute interval between dosing is advised.

Special Populations

• Pregnancy & lactation: Not applicable; Vilitra is intended for male patients only.
• Elderly: No dose reduction is required solely based on age, but comorbidities and concomitant medicines should be reviewed.
• Renal or hepatic impairment: Start with the lowest dose (10 mg) and adjust based on tolerability and clinical response.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Headache - frequently reported, usually mild and transient.
• Facial flushing - a warm sensation often occurring shortly after dosing.
• Indigestion or dyspepsia - may be mitigated by taking the tablet with water and avoiding heavy meals.
• Nasal congestion - occasional runny or stuffy nose.
• Back pain - typically mild and resolves without intervention.

Serious Adverse Events

• Sudden vision loss (non-arteritic anterior ischemic optic neuropathy) - seek immediate medical attention.
• Priapism (prolonged erection lasting > 4 hours) - requires urgent evaluation to prevent tissue damage.
• Severe hypotension - especially when combined with nitrates or potent vasodilators.

Drug Interactions

• Major: Nitrates (any form) - contraindicated due to risk of profound hypotension.
• Moderate: Alpha-blockers, other PDE5 inhibitors, and CYP3A4 inhibitors (ketoconazole, erythromycin, ritonavir). These may increase vardenafil plasma levels and warrant dose adjustment or enhanced monitoring.
• Potential: CYP3A4 inducers such as rifampicin or carbamazepine may reduce efficacy; clinicians may consider alternative therapy if needed.

Food and Lifestyle Interactions

• High-fat meals can delay the onset of action by up to 2 hours; taking Vilitra on an empty stomach may provide faster effect.
• Moderate alcohol intake generally does not interfere, but excessive alcohol can impair erectile response and increase the risk of hypotension.
• No known interaction with tobacco or caffeine, though overall cardiovascular health should be optimised.
• Patients should avoid operating heavy machinery or driving if they experience dizziness or visual disturbances after dosing.

Dosing and Administration Guidelines

• Standard starting dose: 10 mg taken orally about 30 minutes before anticipated sexual activity.
• Dose adjustments: Based on efficacy and tolerability, the dose may be increased to 20 mg or, where clinically appropriate, up to 40 mg or 60 mg. The maximum recommended frequency is once daily.
• Administration tips: Swallow the tablet whole with water; do not crush or chew.
• Missed dose: If a sexual encounter does not occur, the dose should be discarded; do not take an additional dose later the same day.
• Overdose: Symptoms may include severe hypotension, prolonged erection, or fainting. Seek emergency medical care; there is no specific antidote, supportive measures are used.
• Discontinuation: No tapering is required, but patients should discuss any ongoing concerns with their prescriber before stopping.

Individual dosing must always be confirmed by a qualified healthcare professional, taking into account the patient’s overall health and concurrent medications.

Monitoring and Follow-Up

• Cardiovascular assessment before initiating therapy, especially in men with known heart disease.
• Blood pressure should be measured periodically; significant drops after dosing warrant clinical review.
• Vision assessment if patients report visual disturbances.
• Routine laboratory monitoring is not required solely for Vilitra, but liver and kidney function tests may be ordered if underlying disease exists.

Storage and Handling

• Store tablets at room temperature (15-30 °C), away from excess moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use the medication after the expiry date printed on the pack.
• Dispose of unused tablets according to local pharmacy take-back programmes or follow the instructions on the patient-information leaflet.

Medication-Specific Glossary

Phosphodiesterase-5 (PDE5) inhibitor

A drug class that blocks the PDE5 enzyme, enhancing the cGMP pathway to promote smooth-muscle relaxation in the penis.

cGMP (cyclic guanosine monophosphate)

A secondary messenger that mediates vasodilation; its accumulation is central to achieving an erection.

Bioavailability

The proportion of the orally administered dose that reaches systemic circulation unchanged; for vardenafil, oral bioavailability is approximately 15 % due to first-pass metabolism.

Priapism

A prolonged, often painful erection lasting more than four hours that requires urgent medical attention to prevent permanent tissue damage.

CYP3A4

A liver enzyme that metabolises many drugs, including vardenafil; inhibitors or inducers of this enzyme can alter vardenafil levels.

Medical Disclaimer

This article provides educational information about Vilitra and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.